NASDAQ · RVMD
Healthcare · Biotechnology
$188.44
Up+$5.08 (+2.70%)
Updated Oct 14, 2026, 9:08 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RVMD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
RVMD closed at $188.44 after 21 trading sessions, down 8.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $191.57 | $193.61 | $187.14 | $188.44 | 2.94M |
| Oct 12, 2026 | $187.79 | $194.26 | $184.76 | $193.95 | 1.67M |
| Oct 9, 2026 | $186.01 | $193.50 | $184.3701 | $189.76 | 2.21M |
| Oct 8, 2026 | $198.51 | $199.64 | $180.49 | $188.12 | 4.86M |
| Oct 7, 2026 | $198.18 | $203.50 | $196.25 | $200.87 | 1.19M |
| Oct 6, 2026 | $208.57 | $208.57 | $195.00 | $199.87 | 1.63M |
| Oct 5, 2026 | $207.68 | $210.27 | $201.83 | $207.68 | 1.42M |
| Oct 2, 2026 | $205.89 | $208.82 | $204.07 | $206.64 | 1.57M |
| Oct 1, 2026 | $204.00 | $210.88 | $203.26 | $205.89 | 2.1M |
| Sep 30, 2026 | $205.48 | $209.79 | $203.00 | $205.26 | 1.85M |
| Sep 29, 2026 | $201.41 | $204.96 | $200.00 | $204.48 | 1.72M |
| Sep 28, 2026 | $203.97 | $204.98 | $200.98 | $201.74 | 1.81M |
| Sep 25, 2026 | $200.54 | $211.51 | $197.97 | $204.97 | 2.52M |
| Sep 24, 2026 | $190.15 | $201.28 | $189.84 | $199.86 | 4.07M |
| Sep 23, 2026 | $193.30 | $196.7052 | $189.05 | $190.74 | 2.12M |
| Sep 22, 2026 | $191.56 | $195.28 | $191.22 | $192.86 | 1.88M |
| Sep 21, 2026 | $192.605 | $194.93 | $190.57 | $192.76 | 1.89M |
| Sep 18, 2026 | $197.00 | $197.10 | $188.18 | $190.95 | 5.94M |
| Sep 17, 2026 | $198.53 | $202.02 | $194.80 | $196.94 | 1.82M |
| Sep 16, 2026 | $204.84 | $205.15 | $193.58 | $195.92 | 3.04M |
| Sep 15, 2026 | $206.98 | $207.00 | $200.24 | $204.86 | 1.27M |
The latest Smart Investors Daily articles mentioning RVMD.
Company
Market Activity
Research & News
RVMD research
Company profile and research snapshot.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 28, 2026 | Brookline Capital | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 21, 2026 | B of A Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 8, 2026
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $251 to $259.
Yahoo · Oct 7, 2026
After FDA approval of its breakthrough cancer drug Rasonque, Revolution Medicines has pledged to ensure access for all eligible US patients regardless of their ability to pay. Chief executive Mark Goldsmith shares how the company is making it possible and what is next for the company.
Benzinga · Oct 7, 2026
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.
Yahoo · Oct 7, 2026
Revolution Medicines has already begun treating patients in RASolute 309, a global Phase 3 trial testing first-line RASONQUE plus zoldonrasib against gemcitabine and nab-paclitaxel in adults with metastatic RAS G12D pancreatic cancer. This study targets the most common RAS mutation in oncology, RAS G12D, for which there is currently no approved targeted therapy, highlighting the potential impact of Revolution Medicines’ RAS(ON) inhibitor platform. We’ll now examine how launching a pivotal...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RVMD.
